Infectious Disease In Vitro Diagnostics Market
Report ID: SQMIG35A3885
Report ID: SQMIG35A3885
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35A3885 |
Region:
Global |
Published Date: June, 2026
Pages:
157
|Tables:
179
|Figures:
79
Global Infectious Disease In Vitro Diagnostics Market size was valued at USD 24.5 Billion in 2024 and is poised to grow from USD 25.25 Billion in 2025 to USD 32.19 Billion by 2033, growing at a CAGR of 3.08% during the forecast period (2026-2033).
The infectious diseases in vitro diagnostics market is focused on technologies that detect and characterise pathogens in a sample; and it is important, as rapid and accurate test results are critical to supporting patient treatment, guiding public health responses, and ensuring responsible use of antibiotics. Use of rapid, sensitive molecular assays is the primary driver of growth in this segment; advances in PCR and next-generation sequencing, as well as the advent of multiplex panels, have allowed diagnostics to transition away from traditional central laboratory settings and into point-of-care sites, as was demonstrated during the COVID-19 pandemic and the mass testing that occurred, which revealed gaps in capacity and opportunities for innovation. As a result, the evolution of regulatory pathways, reimbursement mechanisms and investment strategies has matured, thereby facilitating adoption of automated laboratory testing systems and digital reporting mechanisms which yield significant measurable improvements in clinical outcomes.
Regulatory flexibility and recognition by payers of the value of diagnostic testing will continue to increase investment by developers in rapid, multiplex, point-of-care assays, whereby quicker test results also reduce the length of hospital stays and unnecessary prescribing of antibiotics. As an example, Xpert MTB/RIF reduced the time to diagnosis for patients with tuberculosis which allowed for more timely initiation of appropriate treatment; similarly, the use of respiratory multiplex panels for patients visiting the emergency department has led to a reduction in the number of people receiving antibiotics when they are not needed. The creation of connectivity platforms that aggregate test results provides opportunities for surveillance and predictive analytics, and will encourage collaboration between manufacturers and health systems to scale and implement decentralized testing programs. Connectivity platforms that aggregate test results create surveillance and predictive analytics opportunities, prompting collaborations among manufacturers and health systems to scale decentralized testing in emerging markets and to embed diagnostics within clinical pathways, which in turn strengthens demand for integrated, value‑based diagnostic solutions.
How is AI Improving Diagnostic Accuracy In The Infectious Disease In Vitro Diagnostics Market?
By use of complex data, the introduction of AI will provide increased diagnostic accuracy through the mining of subtle patterns found in this data. This technology reduces the variability associated with human analysts. Several technologies will enable AI use in infectious disease in vitro diagnostics including machine learning for the interpretation of spectral data, AI imaging for the analysis of diagnostic images and decision support tools that utilize both laboratory output and patient context. Laboratories are currently using these technologies to obtain more accurate and reliable identification of pathogens as well as obtaining consistent and accurate insight into susceptibility of pathogens.
AI will be used for sequencing interpretive analysis and also to develop exploratory models for use with MALDI TOF spectra in order to identify antibiotic resistance patterns. As a result of AI's potential to produce actionalable diagnostic results and reduce uncertainty related to the diagnosis of infections, Bruker announced in April 2026 their plan to introduce additional MALDI Biotyper and IR Biotyper work flows that will utilize AI for determining antibiotic resistance and cloud based identification of patients for rapid insight regarding susceptibility and resulting in greater confidence in clinical laboratory results. The implementation of such technologies enables laboratories to make rapid decisions related to treatment and drives market growth through improved efficiency and increased confidence in the use of AI enabled in vitro diagnostic solutions.
Market snapshot - (2026-2033)
Global Market Size
USD 24.5 Billion
Largest Segment
Reagents & Kits
Fastest Growth
Software & Data Management Solutions
Growth Rate
3.08% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global infectious disease in vitro diagnostics market is segmented by by product type, by technology, by disease type, by application, by end user, by test location and region. Based on by product type, the market is segmented into Reagents & Kits, Instruments, Software & Data Management Solutions and Others. Based on by technology, the market is segmented into Molecular Diagnostics, Immunodiagnostics, Clinical Microbiology, Point-of-care Testing and Others. Based on by disease type, the market is segmented into Viral Infections, Bacterial Infections, Fungal Infections and Parasitic Infections. Based on by application, the market is segmented into Disease Screening, Disease Diagnosis, Treatment Monitoring, Blood Screening and Others. Based on by end user, the market is segmented into Hospitals, Diagnostic Laboratories, Academic & Research Institutes, Blood Banks and Others. Based on by test location, the market is segmented into Laboratory Testing, Point-of-care Testing and Home-based Testing. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
The Molecular Diagnostics segment of the health industry continues to dominate because it has a high level of sensitivity and specificity when trying to detect the pathogen directly. Furthermore, their multiple-panel capabilities and quick turnaround times are driving demand for molecular diagnostics across different types of hospitals, clinics, and laboratories, thereby creating a need for more investments in development of platforms and workflows integration. Additionally, the regulatory acceptance and alignment with Antimicrobial Stewardship practices (i.e., there are ongoing concerns about the overuse and misuse of antibiotics) only adds to the preference by labs for using molecular assays; as such, they will be creating ongoing demand for molecular manufacturing limitations which will influence both procurement and innovation priorities in this market.
As per infectious disease in vitro diagnostics market analysis, immunodiagnostics represent a rapidly growing area as a result of the increasing need for serological tests, antibody surveillance, and rapid antigen tests to support both clinical and public health screening. Some of the factors that are causing increased adoption of immunodiagnostic testing include continued advancements in lateral-flow assays and automated immunoassay platforms; additionally, the expanding use of these tests within outpatient settings and streamlined regulatory pathways have led to the quick adoption of new applications of immunodiagnostics, as well.
The most significant contributor to the Reagents & Kits segment is the consumable components that are required to conduct many different types of infectious disease assays across multiple platforms (e.g., PCR, ELISA, etc.), creating a steadily increasing need for Reagents & Kits by laboratory and clinical users. Because the kits are standardized, laboratories can simplify their work processes, reduce variability among operators, and implement new tests quickly, resulting in larger numbers of contracts for the purchase of reagents and kits over longer periods of time. Strong supplier relationships and added-value technical support from suppliers further support the adoption of reagents and kits, providing laboratories with predictable revenue streams and informing manufacturers' priorities for product development in the market.
As per infectious disease in vitro diagnostics market forecast, the instruments segment is currently experiencing the most rapid growth in the marketplace due to laboratories investing more money on automation and integrated platforms that increase throughput while decreasing hands-on time required by the user. In particular, compact analyzers capable of multiplexing, improved connectivity, modular design, and more, all support the need for laboratory users to upgrade their equipment while also broadening their menu of tests and service models (i.e., number of tests performed) and therefore increasing overall laboratory capacity as well as generating increased upstream demand for consumables.
To get detailed segments analysis, Request a Free Sample Report
A combination of established healthcare delivery systems, extensive laboratory networks, and a concentration of innovative and trusted companies that manufacture diagnostics technologies in North America are all contributors to the region’s position as a leader in the development of new tests. By having an integrated clinical and public health infrastructure, test developers can quickly implement new tests into clinical practice and conduct extensive clinical validation supporting the validity of these tests. The existence of favourable reimbursement structures and regulatory processes has minimized barriers to market access for diagnostic tests, while stable levels of investment in research and product development allow for the rapid accumulation of products that will eventually be commercialized. There is a high degree of collaboration between diagnostic manufacturers/ developers, academic institutions, and government organisations to improve detection, diagnosis and treatment of infectious diseases by using data collected from real-world use to motivate the development of new tests and translate the success of breakthrough technologies into practice. Experienced professionals who have expertise in obtaining market access are available to work with hospitals and outpatient care settings to assist in overcoming barriers to implementing tests. The continued growth of clinical trials supporting the development of new tests will allow the continuous improvement of tests by generating data that reinforces physician trust in their use and confirms their position as leaders in the marketplace.
In the United States, there is a highly developed infectious disease in vitro diagnostics market consisting of many reference laboratories, the presence of many of the leading companies producing these types of tests, and extensive available resources to facilitate rapid commercial development. The strong collaborative partnerships between the academic medicine and industry have enabled translational research efforts and validation of assays. Additionally, there is a high level of expertise in the United States regarding market access which offsets the complexity of reimbursement. Finally, the demand for rapid molecular and point of care testing is being driven by large hospital systems and public health agencies.
The Canadian infectious disease in vitro diagnostics market exists within the context of a publicly funded health system with established centralized laboratory networks. There is a strong emphasis in Canada on equitable access to healthcare for all Canadians and, therefore, provincial laboratory strategies focus on developing and expanding disease surveillance and diagnostic capacity with an emphasis on fostering strong collaborations between domestic manufacturers and communities of research and clinical practice. Therefore, both the federal and provincial government procurement policies and regulatory framework promote the adoption of molecular and rapid diagnostic tests while continuing to invest in deploying point of care services in areas of need and integrating the work of clinical and public health laboratories.
Europe is advancing rapidly due to a combination of regulatory harmonization efforts, strong regional manufacturing expertise, and evolving clinical needs that prioritize rapid detection and antimicrobial stewardship. National health authorities and pan European bodies emphasize surveillance and preparedness, creating demand for validated molecular, immunoassay, and point of care technologies. An active ecosystem of specialized diagnostics firms, public research institutions, and procurement consortia facilitates cross border adoption and scale up. Reimbursement reforms and investment in digital laboratory connectivity further ease integration into clinical workflows. Established centers of excellence in key countries drive early adoption and export of best practice protocols, while public private partnerships mobilize resources for validation and deployment of novel assays across care settings.
Infectious Disease In Vitro Diagnostics Market in Germany is anchored by a robust medical technology industry, dense hospital laboratory infrastructure, and strong links between industry and research institutes. Clinical laboratories prioritize quality, standardized workflows and assay validation, supporting uptake of advanced molecular platforms. National procurement practices and laboratory networks encourage consolidation, while German manufacturers and testing centers influence regulatory expectations and clinical guidelines across the region through export and collaboration.
Infectious Disease In Vitro Diagnostics Market in the United Kingdom is driven by an innovation ecosystem connecting academic research, hospital trusts, and diagnostics companies. Focus on rapid translation of novel assays, flexible evaluation pathways, and deployment within healthcare networks accelerates adoption. Emphasis on digital integration and interoperability with electronic health records, and partnerships to simplify procurement, fosters early market entry for molecular and point of care solutions and clinical validation.
Infectious Disease In Vitro Diagnostics Market in France is emerging from coordinated public health initiatives, expanding biotech capabilities, and focus on diagnostic self reliance. Regional hospital laboratories drive validation of novel assays and support integration into clinical pathways. Strategic partnerships between manufacturers, clinical laboratories, and research organizations enable piloting of rapid testing models. Policy attention to procurement and laboratory networking is creating conditions for broader uptake and sustained industry maturation.
Asia Pacific is bolstering its presence through coordinated investment in laboratory capacity, growth of capable domestic manufacturers, and progressive regulatory enhancements that shorten time to clinical adoption. National programs emphasize surveillance, decentralized testing, and integration of diagnostics with digital health platforms, enabling faster case detection across varied care settings. Strong industrial ecosystems in key markets support scale up of molecular and point of care technologies, while collaborations with international partners accelerate knowledge transfer and validation. Workforce development and laboratory networking strengthen routine diagnostic capacity. Japan and South Korea contribute advanced assay development and manufacturing quality that set regional benchmarks. Regional procurement cooperation and policy measures encourage standardization and broader distribution of new diagnostics.
Infectious Disease In Vitro Diagnostics Market in Japan is defined by a mature medtech sector, deep expertise in assay development, and widespread laboratory automation. Strong quality management and clinical evaluation underpin clinician confidence, while domestic manufacturers invest in molecular platforms and testing. Close ties between industry, academic centers, and hospital networks support iterative product improvement and validation. Export production and supplier relationships with regional partners amplify Japan influence across markets.
Infectious Disease In Vitro Diagnostics Market in South Korea is propelled by agile biotech and diagnostics firms, strong manufacturing capabilities, and adoption of laboratory automation solutions. A supportive regulatory environment and close collaboration between industry and clinical centers facilitate swift validation and deployment of novel assays. Emphasis on digital connectivity and data integration extends diagnostic reach. Export strategies and partnerships enable effective leverage of regional supply chains and clinical collaborations.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Advances In Diagnostic Technologies
Increasing Demand For Rapid Testing
Regulatory Complexity And Variability
High Cost Of Advanced Assays
Request Free Customization of this report to help us to meet your business objectives.
Competitive landscape in global infectious disease IVD is intensifying as decentralization and rapid point of care testing reshape routes to market. Industry players pursue targeted M&A and platform acquisitions to secure point of care pipelines. OraSure’s acquisition of Sherlock Biosciences on December 19, 2024 illustrates consolidation to access CRISPR and rapid molecular platforms. Technology partnerships that combine sequencing and AI with sample prep, for example Oxford Nanopore’s collaboration with Day Zero Diagnostics, are driving product differentiation.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global infectious disease IVD market is driven primarily by rapid, sensitive molecular assays as a key driver, enabling faster, more accurate pathogen detection and decentralization of testing. A major restraint is regulatory complexity and variability that slows approvals and raises development costs. The dominating region is North America, supported by mature healthcare systems, strong manufacturers and favorable reimbursement. The dominating segment is Molecular Diagnostics, led by PCR and sequencing platforms that enable multiplex, high‑sensitivity testing. A second driver is AI and data integration, which sharpens interpretation, streamlines workflows and strengthens surveillance efforts across care settings and guides investment choices.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 24.5 Billion |
| Market size value in 2033 | USD 32.19 Billion |
| Growth Rate | 3.08% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Infectious Disease In Vitro Diagnostics Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Infectious Disease In Vitro Diagnostics Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Infectious Disease In Vitro Diagnostics Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Infectious Disease In Vitro Diagnostics Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Infectious Disease In Vitro Diagnostics Market size was valued at USD 24.5 Billion in 2024 and is poised to grow from USD 25.25 Billion in 2025 to USD 32.19 Billion by 2033, growing at a CAGR of 3.08% during the forecast period (2026-2033).
Competitive landscape in global infectious disease IVD is intensifying as decentralization and rapid point of care testing reshape routes to market. Industry players pursue targeted M&A and platform acquisitions to secure point of care pipelines. OraSure’s acquisition of Sherlock Biosciences on December 19, 2024 illustrates consolidation to access CRISPR and rapid molecular platforms. Technology partnerships that combine sequencing and AI with sample prep, for example Oxford Nanopore’s collaboration with Day Zero Diagnostics, are driving product differentiation. 'Roche Diagnostics', 'Abbott Laboratories', 'Danaher Corporation', 'Thermo Fisher Scientific', 'Siemens Healthineers', 'bioMérieux', 'QIAGEN', 'Becton Dickinson', 'Hologic', 'Bio-Rad Laboratories', 'Sysmex Corporation', 'PerkinElmer', 'OraSure Technologies', 'Cepheid', 'Grifols', 'QuidelOrtho', 'Seegene', 'Mindray Medical International', 'Agilent Technologies', 'Fujirebio'
Continual improvements in assay sensitivity, multiplexing capabilities, and automation enable broader pathogen detection and streamline laboratory workflows, increasing clinical utility and adoption across diagnostic settings. Enhanced platforms reduce sample-to-answer time while supporting diverse specimen types, which encourages laboratories and clinicians to integrate more in vitro diagnostic solutions into routine practice. These technological advancements lower barriers to implementation by simplifying processes and improving reproducibility, fostering confidence among end users and healthcare systems and thereby contributing to sustained market expansion driven by demand for reliable, comprehensive infectious disease testing.
Point Of Care Expansion: Healthcare providers and clinics are adopting rapid, decentralized infectious disease tests to improve access and accelerate timely clinical decisions. The shift towards compact, user friendly platforms drives demand for assays that perform reliably outside laboratories, enabling treatment and containment. Manufacturers focus on simplified workflows, regulatory pathway alignment, and partnerships with primary care networks to scale deployment. This trend fosters testing coverage, reduces diagnostic delays, and expands market reach into outpatient, emergency, and resource limited settings where laboratory infrastructure is constrained.
Why does North America Dominate the Global Infectious Disease In Vitro Diagnostics Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
